Chair, Dept. of Neurosurgery, Co-Director, Neuroscience Institute, Henry Ford Health System and Director, Henry Ford Center for Cancer Surgery

Neurosurgery

Steven N. Kalkanis, MD practices Neurosurgery. He attended Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School has a rank of 1 in research and a 12 in primary care He over the years received 5 awards: "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification", "Back Pain Recognition Program", "Spine Care Recognition" and "Fellow (FAANS)". Dr. Steven N. Kalkanis is a published doctor and has 70 publications published. The lastest was: 'Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.' Steven Kalkanis accepts all Medicare patients.

Publications

---

• The role of imaging in the management of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
• The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
• The role of emerging therapy in the management of patients with diffuse low grade glioma.
• The role of biopsy in the management of patients with presumed diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
• Identification of regions of normal grey matter and white matter from pathologic glioblastoma and necrosis in frozen sections using Raman imaging.
• The role of radiotherapy in the management of patients with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
• The role of surgery in the management of patients with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
• Management of patients with recurrence of diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
• The role of neuropathology in the management of patients with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
• Deep brain stimulation for obsessive-compulsive disorder: systematic review and evidence-based guideline sponsored by the american society for stereotactic and functio...
• Clinical practice guidelines in the AANS/CNS Section on Tumors: past, present and future directions.
• Raman molecular imaging of brain frozen tissue sections.
• Through the patient's eyes: the value of a comprehensive brain tumor center.
• Through the patient's eyes: an emphasis on patient-centered values in operative decision making in the management of malignant glioma.
• Vision 20/20: The role of Raman spectroscopy in early stage cancer detection and feasibility for application in radiation therapy response assessment.
• The role of imaging in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline.
• The role of cytoreductive surgery in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline.
• Introduction, rationale, and methodology.
• The role of neuropathology in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline.
• The role of targeted therapies in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline.
• The role of cytotoxic chemotherapy in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline.
• The role of radiotherapy in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline.
• It is Time to Re-evaluate the Management of Patients with Brain Metastases.
• Current approaches to the treatment of metastatic brain tumours.
• Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections.
• Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
• Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
• Neuro-Oncologic Applications of Exosomes, Microvesicles, and Other Nano-sized Extra-cellular Particles.
• Glioblastoma cell line-derived spheres in serum‑containing medium versus serum-free medium: A comparison of cancer stem cell properties.
• Radiosurgery to the Surgical Cavity as Adjuvant Therapy for Resected Brain Metastasis.
• Heparanase expression is associated with histone modifications in glioblastoma.
• Evidence-based guidelines for the management of brain metastases.
• Heparanase expression of glioma in human and animal models.
• The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.
• The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
• Evidence-linked, clinical practice guidelines-getting serious; getting professional.
• The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.
• Methodology used to develop the AANS/CNS management of brain metastases evidence-based clinical practice parameter guidelines.
• Evidence-based clinical practice parameter guidelines for the treatment of patients with metastatic brain tumors: introduction.
• The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice gui...
• The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
• The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
• The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline.
• The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.
• The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells.
• Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model.
• Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma.
• Subclinical photodynamic therapy treatment modifies the brain microenvironment and promotes glioma growth.
• Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion.
• Combination of surgical resection and photodynamic therapy of 9L gliosarcoma in the nude rat.
• Paraplegia after tethered cord surgery: an uncommon combined anomaly of spinal arteriovenous fistula and sacral lipoma--case report.
• Microvascular decompression surgery in the United States, 1996 to 2000: mortality rates, morbidity rates, and the effects of hospital and surgeon volumes.
• Neck and Back Pain in the Elderly.
• Surgical treatment of solitary brain metastases.
• Low-dose photodynamic therapy increases endothelial cell proliferation and VEGF expression in nude mice brain.
• Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo.
• Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells.
• Intracellular free calcium mediates glioma cell detachment and cytotoxicity after photodynamic therapy.
• Odyssey of hope: a physician's guide to communicating with brain tumor patients across the continuum of care.
• Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
• Post-acute response of 9L gliosarcoma to Photofrin-mediated PDT in athymic nude mice.
• Pigmented central neurocytoma.
• SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion.
• Delayed complications thirty-six years after hemispherectomy: a case report.
• Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.
• Quality of life following surgery for intracranial meningiomas at Brigham and Women''s Hospital: a study of 164 patients using a modification of the functional assessm...
• FACT-MNG: tumor site specific web-based outcome instrument for meningioma patients.
• A quantitative model of tumor-induced angiogenesis in the nude mouse.
• Using behavioral measurement to assess tumor progression and functional outcome after antiangiogenic treatment in mouse glioma models.

Schools

---

• HARVARD MED SCH

• Massachusetts General Hospital

Procedures Preformed

---

• Craniectomy, Craniotomy, Surgery of Skull Base, Neuroendoscopy
• Dural Repair or Other Spinal Spinal Cord Repair
• Herniated Disc Surgery
• Lamina Procedures (incl. Laminectomy, Laminoplasty, Laminotomy)
• View All

Doctors Specialties

---

• Neurosurgery
• Surgical Oncology

Accepted Insurances

---

• Choice Plus POS II
• Amerigroup (Wellpoint)
• Blue Card PPO
• Blue Cross Blue Shield of Illinois PPO
• Blue Care Network PCP Focus Network
• Group Employees PPO
• Cigna HMO
• Cigna PPO
• Great West Healthcare-Cigna PPO
• Open Access Plus
• Cofinity PPO
• Commercial Insurance Company
• First Health (Coventry Health Care) PPO
• Health Alliance
• Preferred PPO
• Choice Care PPO
• Medicare MCR
• Molina
• MultiPlan PPO
• PHCS Network PPO
• NGS CoreSource
• Priority PPO
• Choice Plus POS
• Navigate HMO
• Navigate POS
• Options PPO

Awards

---

• Regional Top Doctor
• CMS Meaningful Use Stage 1 Certification
• Back Pain Recognition Program
• Spine Care Recognition
• Fellow (FAANS)

Education

---

• Massachusetts General Hospital
• Harvard Medical School

Hospital

---

• Henry Ford Hospital

Drug Facts

---

NPI NUMBER		1861567505
NPPES Provider LastName		KALKANIS
NPPES Provider FirstName		STEVEN
NPPES Provider ZIPCode		48202
NPPES Provider State		MI
Specialty Description		Neurosurgery
Total Claim Count		73.0
Distinct Opioid Count		1.0
Opioid Claim Count		11.0
Percent Opioid Claims		15.07

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1861567505
Last Name Of The Provider	KALKANIS
First Name Of The Provider	STEVEN
View All

Similar Doctors

---

	Dr. Matthew R. Schreckinger, MD This Doctor is OpenDoctor Recommended.
	Dr. Atsushi Yoshida, MD This Doctor is OpenDoctor Recommended.
	Dr. A B. Eisenbrey Jr., MD
	Dr. S David Nathanson, MD This Doctor is OpenDoctor Recommended.
	Dr. Marwan S. Abouljoud, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Sanjay E. Patra, MD This Doctor is OpenDoctor Recommended.
	Dr. Amit Amit, MD
	Dr. David S. Kwon, MD This Doctor is OpenDoctor Recommended.
	Dr. Brandon J. Bond, MD
	Dr. Paritosh Pandey, MD This Doctor is OpenDoctor Recommended.
	Dr. Lara W. Massie, MD
	Dr. Arianne J. Boylan, MD
	Dr. Thomas K. Noh, MD
	Dr. Felix Umansky, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Adam M. Robin, MD This Doctor is OpenDoctor Recommended.
	Dr. Elizabeth D. Klein, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog